本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
印度普納 2023年7月2日 /美通社/ -- 根據 Growth Market Reports 最近的市場研究報告，標題為「2023-2031 年全球品牌保護軟件市場細分 - 按類型、應用、解決方案、組織規模、行業和地區：規模、份額、趨勢和機遇分析」，該市場規模在 2022年 為 2.9154 億美元，預計到 2031 年以 21.6% 的複合年增長率超過 16947 億美元。 Growth_Market_Reports_Logo1 報告涵蓋的主要參與者包括 OpSec PhishLabs Red Points Coresearch Inc. Resolver RiskIQ Ruvixx Brand Shield Brandverity Corporation Service Company Hubstream, Inc. LashBack Wolters Kluwer N.V. Authlink 在這裡下載 PDF 樣本：https://growthmarketreports.com/request-sample/147 該報告涵蓋了可能改變市場動態的新興趨勢、市場驅動因素、增長機遇和受限制的數據。提供了對市場細分、行業參與者和關鍵策略的深入分析，協助市場參與者擴大業務。 如有任何問題：https://growthmarketreports.com/enquiry-before-buying/147 關鍵收穫： 品牌保護軟件分析和管理有關公司產品和服務的詳細資訊。 創建品牌意識和保護品牌免受欺詐的需求增加，預計將推動市場增長。 地端軟件細分預計將以最快的複合年增長率擴張，因為這是安裝和運行在公司內部伺服器上的，這會更加安全。 大型企業細分預計將佔據主要的市場份額，因為跨國公司的滲透率不斷提升。 消費品細分預計將主導市場，因為產品行業正在快速擴張。 北美預計將在預測期內主導市場，因為該地區有大型的管理安全服務供應商。 獲得 262 頁報告的完整存取權限：https://growthmarketreports.com/checkout/147 涵蓋的細分 類型 地端 雲端 應用 廣告監測 內容保護智能 網站屏蔽智能 社交媒體監測 防偽 市場監測 其他 解決方案 域名監測 移動應用監測 防偽 其他 組織規模 中小企業 大型企業 行業 IT 與電訊 媒體與娛樂 能源與公用事業 消費品與零售 醫療保健 銀行、金融服務和保險 其他 地區 亞太地區 北美洲 拉丁美洲 歐洲 中東及非洲 相關報告： 零售採購和採購市場 全球品牌管理解決方案市場 全球零售智能軟件市場 全球品牌保護工具市場 聯絡方式： 電話：+1 909 414 1393 電子郵件：sales@growthmarketreports.com 網址：https://growthmarketreports.com LinkedIn：https://www.linkedin.com/company/growth-market-report/
PUNE, India, July 3, 2023 /PRNewswire/ -- According to a recent market study by Growth Market Reports, titled, "Global Brand Protection Software Market Segments - By Types, By Applications, By Solution, By Organization Size, By Industries, and Region: Size, Share, Trends and Opportunity Analysis, 2023-2031", the market size was USD 291.54 Mn in 2022 and is expected to surpass USD 1,694.70 Bn at a CAGR of 21.6% by 2031. Growth_Market_Reports_Logo1 Key Players Covered OpSec PhishLabs Red Points Coresearch Inc. Resolver RiskIQ Ruvixx Brand Shield Brandverity Corporation Service Company Hubstream, Inc. LashBack Wolters Kluwer N.V. Authlink Download PDF Sample here: https://growthmarketreports.com/request-sample/147 The report covers data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics. It provides an in-depth analysis of the market segments, industry players, and crucial strategies that helps market players to expand their business. For Any Questions: https://growthmarketreports.com/enquiry-before-buying/147 Key Takeaways: Brand protection software analyzes and manages detailed information about a company's products and services. Rising adoption in creating brand awareness and growing requirements to protect brands from fraud are expected to drive the market. The on premise software segment is projected to expand at the fastest CAGR, as it is installed and operated from the company's in-house server, which makes it more secure. The large enterprise segment is anticipated to hold a major market share, owing to the increasing penetration of multinational companies. The consumer goods segment is expected to dominate the market, due to the rapid expansion of product industries. North America is expected to dominate the market during the forecast period, owing to the presence of large managed security service providers. Get Full Access to 262 Pages Report: https://growthmarketreports.com/checkout/147 Segments Covered Types On Premise On Cloud Applications Advertising Monitoring Content Protection Intelligence Site Blocking Intelligence Social Media Monitoring Anti-Counterfeiting Market Place Monitoring Others Solution Domain monitoring Mobile-app monitoring Anti-counterfeit Others Organization Size SMEs Large Enterprise Industries IT & Telecom Media and Entertainment Energy And Utilities Consumer Goods And Retail Healthcare BFSI Others Region Asia Pacific North America Latin America Europe Middle East & Africa Related Reports: Retail Sourcing and Procurement Market Global Brand Management Solutions Market Global Retail Intelligence Software Market Global Brand Protection Tools Market Contact:Phone: +1 909 414 1393Email: sales@growthmarketreports.comWeb: https://growthmarketreports.comLinkedIn: https://www.linkedin.com/company/growth-market-report/
美國羅克維爾和中國蘇州2023年7月3日 /美通社/ -- 信達生物制藥集團（香港聯交所股票代碼：01801），一家致力於研發、生產和銷售腫瘤、自身免疫、代謝、眼科等重大疾病領域創新藥物的生物制藥公司，與馴鹿生物，一家致力於細胞創新藥物研發、生產和銷售的生物制藥公司，共同宣布國家藥品監督管理局已正式批准雙方共同開發及商業化的細胞免疫治療產品福可蘇®（伊基奧侖賽注射液，信達生物研發代號：IBI326；馴鹿生物研發代號：CT103A）的新藥上市申請（NDA），用於治療復發難治多發性骨髓瘤成人患者，既往經過至少3線治療後進展（至少使用過一種蛋白酶體抑制劑及免疫調節劑）。 福可蘇®（伊基奧侖賽注射液）是一種針對B細胞成熟抗原（BCMA）的CAR-T細胞療法，以慢病毒為基因載體轉染自體T細胞，CAR包含全人源scFv、CD8a 鉸鏈和跨膜、4-1BB共刺激和CD3ζ激活結構域。基於嚴格的分子結構篩選，通過全面的體內外功能評價，福可蘇®具有快速和強勁的療效，並有突出的體內持久存續性，可使患者獲得更高、更深的緩解，持續守護多發性骨髓瘤患者。 此次獲批是基於FUMANBA-1臨床研究數據(CTR20192510,NCT05066646)。FUMANBA-1臨床研究是一項評估伊基奧侖賽注射液治療復發/難治性多發性骨髓瘤患者的中國多中心I/II期注冊臨床試驗。最新長期隨訪數據更新在2023年美國臨床腫瘤學術年會（ASCO）以壁報形式展示（摘要編號：8025）。 最新研究結果顯示出伊基奧侖賽注射液優異的有效性和安全性。103例接受1.0×106 CAR-T 細胞/Kg的受試者，中位隨訪時間為13.8（0.4, 27.2）個月。 101例療效可評估的受試者的總緩解率（ORR）達到96%，嚴格意義的完全緩解/完全緩解（sCR/CR）率為74.3%（75/101），中位達緩解時間（mTTR）僅16天，12個月的PFS率為78.8%；95%的受試者達到微小殘留病灶（MRD）陰性，獲得完全緩解（CR）及以上療效的受試者均達到MRD陰性；12例既往接受過CAR-T治療的多發性骨髓瘤受試者中，9例獲得CR，5例獲得sCR，其中4例維持sCR超過18個月。89例未接受過既往CAR-T治療的受試者中，sCR/CR率更是達到了78.7%。 103例受試者中，僅1例受試者出現≥3級的細胞因子釋放綜合征（CRS），2例受試者出現1-2級免疫效應細胞相關神經毒性綜合征（ICANS），所有受試者的CRS和ICANS均在治療後得到緩解。 在回輸後達到12個月和24個月的受試者中分別有50%和40%的受試者仍可檢測到CAR-T細胞。僅19.4%的受試者在回輸後檢測出抗CAR抗體（ADA）陽性。 福可蘇®中國注冊臨床試驗主要研究者，中國醫學科學院血液病醫院的邱錄貴教授和華中科技大學同濟醫學院附屬同濟醫院李春蕊教授表示：「多發性骨髓瘤的治療在中國仍然存在大量未被滿足的臨床需求，福可蘇®作為全人源BCMA CAR-T療法，顯示出卓越的療效，為骨髓瘤患者帶來深度持久的緩解，延長其高質量生存。福可蘇®的獲批也給臨床醫生提供了更多的選擇，改善臨床中多線多發性骨髓瘤治療選擇受限的局面。」 信達生物制藥集團高級副總裁周輝博士表示：「多發性骨髓瘤是血液系統常見高發的惡性腫瘤，復發耐藥在治療中幾乎不可避免，臨床亟需良好耐受性和深度持久響應的治療手段。福可蘇®作為一種創新的全人源細胞療法，注冊臨床研究的長期隨訪數據展現了強效持久的療效和優異的安全性特征，有望為復發難治多發性骨髓瘤患者帶來新的生存希望。我們很高興福可蘇®新藥上市成功獲批，期待其作為國內首款上市的BCMA CAR-T產品，惠及中國的多發性骨髓瘤患者。」 馴鹿生物創始人兼董事長張金華女士表示：「非常高興福可蘇®新藥上市的成功獲批，這是馴鹿生物的重要裡程碑。福可蘇®不僅是馴鹿生物的首款上市產品，也是全球第一款商業化全人源CAR-T產品。同時，它也是中國第一款自主研發並且全流程自主生產的CAR-T細胞療法、國內首個獲批的靶向BCMA CAR-T產品以及國內首款獲批的治療多發性骨髓瘤的細胞治療產品。福可蘇®出色的臨床療效和安全性，將為多發性骨髓瘤患者提供一種全新的突破性治療選擇，帶來治愈的希望。」 關於多發性骨髓瘤（MM） 多發性骨髓瘤（MM）是最常見的血液癌症之一，是一種克隆性漿細胞異常增殖的惡性疾病。對於初治的多發性骨髓瘤患者，常用的一線治療包括多種藥物組合的誘導治療、鞏固治療和維持治療，以及自體干細胞移植(ASCT)等。對於大多數的患者，經過疾病穩定期後也會不可避免地進入復發、難治的治療困局。因此，復發/難治多發性骨髓瘤患者仍存在巨大的臨床未滿足需求。根據弗若斯沙利文報告：中國MM的年新發病人數由2018年20,100人增至 2022年22,400人，預計2027年將增長至25,700人。 關於福可蘇®（伊基奧侖賽注射液） 福可蘇®（伊基奧侖賽注射液）是一種針對B細胞成熟抗原（BCMA）的CAR-T細胞療法，以慢病毒為基因載體轉染自體T細胞，CAR包含全人源scFv、CD8a 鉸鏈和跨膜、4-1BB共刺激和CD3ζ激活結構域。基於嚴格的分子結構篩選，通過全面的體內外功能評價，福可蘇®具有快速和強勁的療效，並有突出的體內持久存續性。 福可蘇®（伊基奧侖賽注射液）已獲中國國家藥品監督管理局（NMPA）批准，用於治療復發/難治性多發性骨髓瘤，由信達生物和馴鹿生物共同合作開發和商業化。 此外，伊基奧侖賽注射液獲FDA授予「孤兒藥（ODD）」認定，用於治療復發/難治性多發性骨髓瘤，並獲得美國FDA批准注冊臨床。2023年2月，伊基奧侖賽注射液再獲FDA再生醫學先進療法（RMAT）資格和快速通道（FT）資格。除多發性骨髓瘤外，伊基奧侖賽注射液新增擴展適應症-抗體介導的視神經脊髓炎譜系疾病（NMOSD）的臨床試驗申請已獲NMPA批准。 關於信達生物 「始於信，達於行」，開發出老百姓用得起的高質量生物藥，是信達生物的理想和目標。信達生物成立於2011年，致力於開發、生產和銷售腫瘤、自身免疫、代謝、眼科等重大疾病領域的創新藥物。2018年10月31日，信達生物制藥在香港聯合交易所有限公司主板上市，股票代碼：01801。 自成立以來，公司憑借創新成果和國際化的運營模式在眾多生物制藥公司中脫穎而出。建立起了一條包括35個新藥品種的產品鏈，覆蓋腫瘤、自身免疫、代謝、眼科等多個疾病領域，其中7個品種入選國家「重大新藥創制」專項。公司已有 9個產品獲得批准上市，它們分別是信迪利單抗注射液（達伯舒®），貝伐珠單抗注射液（達攸同®），阿達木單抗注射液（蘇立信®），利妥昔單抗注射液（達伯華®），佩米替尼片（達伯坦®），奧雷巴替尼片（耐立克®）， 雷莫西尤單抗注射液（希冉擇®），塞普替尼膠囊（睿妥®），伊基奧侖賽注射液（福可蘇®），2個品種在NMPA審評中，6個新藥分子進入III期或關鍵性臨床研究，另外還有18個新藥品種已進入臨床研究。 信達生物已組建了一支具有國際先進水平的高端生物藥開發、產業化人才團隊，包括眾多海歸專家，並與美國禮來制藥、羅氏、賽諾菲、Adimab、Incyte和MD Anderson 癌症中心等國際合作方達成30項戰略合作。 信達生物在不斷自研創新藥物、謀求自身發展的同時，秉承經濟建設以人民為中心的發展思想。多年來，始終心懷科學善念，堅守「以患者為中心」，心系患者並關注患者家庭，積極履行社會責任。公司陸續發起、參與了多項藥品公益援助項目，讓越來越多的患者能夠得益於生命科學的進步，用得上、用得起高質量的生物藥。至2023年3月，信達生物患者援助項目已惠及16余萬普通患者，藥物捐贈總價值數億元。 信達生物希望和大家一起努力，提高中國生物制藥產業的發展水平，以滿足百姓用藥可及性和人民對生命健康美好願望的追求。 詳情請訪問公司網站：www.innoventbio.com或公司領英賬號：Innovent Biologics。 關於馴鹿生物 馴鹿生物是一家致力於細胞創新藥物研發、生產和銷售的生物制藥公司。公司以開發血液腫瘤細胞類藥物和抗體藥物為創新基石，向實體瘤和自身免疫疾病拓展，擁有完整的從早期發現、臨床開發、注冊申報到商業化生產的全流程能力。公司自行開發的五大技術平台包括全人源抗體開發平台、免疫細胞藥物開發平台、全流程生產及檢定技術平台、藥理藥效平台及臨床開發平台。 公司現有10余個在研品種處於不同研發階段，其中進展最為迅速的伊基奧侖賽注射液（全人源BCMA嵌合抗原受體自體T細胞注射液）上市申請（NDA）已獲國家藥監局（NMPA）批准，並已獲得美國FDA批准注冊臨床，用於治療復發/難治多發性骨髓瘤，該產品被NMPA納入「突破性治療藥物」品種，並先後獲FDA授予「孤兒藥（ODD）」認定及再生醫學先進療法（RMAT）和快速通道(FT)資格。除多發性骨髓瘤外，伊基奧侖賽注射液新增擴展適應症-AQP4-IgG陽性的視神經脊髓炎譜系疾病（Neuromyelitis Optica Spectrum Disorder，NMOSD）的臨床試驗申請（IND）已獲NMPA批准；公司自主研發的創新候選產品CT120（全人源CD19/CD22雙靶點CAR-T細胞注射液）已進入臨床研究階段，適應症分別為CD19/CD22陽性的復發/難治B細胞非霍奇金淋巴瘤（B-NHL）和復發/難治急性B淋巴細胞白血病（B-ALL），並已獲得FDA授予「孤兒藥 (ODD)」認定，用於治療急性淋巴細胞白血病；IASO-782注射液臨床試驗IND已完成FDA審評，獲准在美國開展針對自身免疫性血液系統疾病-自身免疫性血小板減少症（ITP）和溫抗體型自身免疫性溶血性貧血(wAIHA)的臨床試驗。 公司先後和海外細胞治療公司Sana Therapeutics，Cabaletta Bio及Umoja Biopharma達成了基於馴鹿生物臨床驗證全人源的CAR結構或序列的BD授權或研發合作，積極探索下一代細胞治療產品的開發。馴鹿生物憑借其強大的管理團隊、創新的產品線、自有的GMP生產和超強的臨床開發能力，旨在提供變革性、可治愈的創新型療法，以滿足中國乃至世界各地患者未滿足的醫療需求。 了解更多信息，請訪問公司官網：www.iasobio.com 或領英賬號：www.linkedin.com/company/iasobiotherapeutics。 信達生物前瞻性聲明 本新聞稿所發布的信息中可能會包含某些前瞻性表述。這些表述本質上具有相當風險和不確定性。在使用「預期」、「相信」、「預測」、「期望」、「打算」及其他類似詞語進行表述時，凡與本公司有關的，均屬於前瞻性表述。本公司並無義務不斷地更新這些預測性陳述。 這些前瞻性表述是基於本公司管理層在做出表述時對未來事務的現有看法、假設、期望、估計、預測和理解。這些表述並非對未來發展的保證，會受到風險、不確性及其他因素的影響，有些是超出本公司的控制范圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展的影響，實際結果可能會與前瞻性表述所含資料有較大差別。 本公司、本公司董事及雇員代理概不承擔 (a) 更正或更新本網站所載前瞻性表述的任何義務;及 (b) 若因任何前瞻性表述不能實現或變成不正確而引致的任何責任。
ROCKVILLE, Md. and SUZHOU, China, July 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotechnology ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announce that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO® (Equecabtagene Autoleucel, co-developed and co-commercialized by Innovent and IASO Bio, Innovent R&D code: IBI326, IASO Bio R&D code: CT103A), the first fully-human BCMA-directed chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. FUCASO® (Equecabtagene Autoleucel) is a BCMA-directed CAR T cell therapy, using lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully-human scFv, CD8a hinge and transmembrane, and 4-1BB-mediated co-stimulation and CD3ζ activation domains. Based on rigorous selection and screening of the molecular structures, and comprehensive in vivo and in vitro evaluation, FUCASO® has demonstrated rapid and potent efficacy as well as prolonged persistency in RRMM patients, providing higher and deeper responses and long-term clinical benefit. The NDA approval was based on the results from the FUMANBA-1 clinical study (CTR20192510, NCT05066646), a multi-center Phase I/II registrational clinical trial conducted in China to evaluate the efficacy of Equecabtagene Autoleucel in patients with RRMM. In June 2023, updated data from this ongoing study was presented as a poster presentation (Abstract Number: 8025) at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), in which Equecabtagene Autoleucel demonstrated remarkable efficacy and favorable safety profiles. A total of 103 subjects received a dose of 1.0×106 CAR-T cells/kg, with a median follow-up time of 13.8 (0.4, 27.2) months. Among the 101 evaluable patients, the overall response rate (ORR) was 96%, and the stringent complete response/ complete response (sCR/CR) rate was 74.3%. Median time to response (mTTR) was only 16 days, and the 12-month PFS rate was 78.8%. 95% of the patients achieved minimal residual disease (MRD) negativity, and all sCR/CR patients achieved MRD negativity. Of the 12 patients with prior CAR-T therapy, 9 achieved CR, and 5 achieved sCR (including 4 patients that sustained sCR for over 18 months post-infusion). In 89 patients without prior CAR-T therapy, 78.7% reached sCR/CR. Of the 103 patients, only one experienced grade ≥3 cytokine release syndrome (CRS), and 2 experienced grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS). All patients with CRS or ICANS recovered after the treatment. Equecabtagene Autoleucel was still detectable in 50% and 40% respectively of the patients who completed 12-month and 24-month follow-ups after infusion. Only 19.4% of the patients were anti-drug antibody (ADA)-positive after Equecabtagene Autoleucel infusion. The Principal Investigators of FUMANBA-1 study, Prof. Lugui Qiu, MD, Chinese Academy of Medical Science Hematology Hospital, and Prof. Chunrui Li, MD, PhD, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology: "There's a significant unmet clinical need for the treatment of multiple myeloma (MM) in China. As a fully-human BCMA CAR-T therapy, FUCASO® has demonstrated remarkable efficacy, with evidence of deep and durable response for high-quality survival for MM patients. We believe that FUCASO's® approval will offers clinicians a novel breakthrough option benefiting patients with later-line RRMM." Dr. Hui Zhou, Senior Vice President of Innovent Biologics, stated, "Multiple myeloma is a common hematology malignant disease with high incidence rate, and relapse and refractory are almost inevitable after current treatments. There's an urgent unmet need of a treatment with well-tolerated and long persistence for RRMM patients in China. FUCASO®, as an innovative fully-human BCMA-directed T cell therapy, has demonstrated robust and long-lasting efficacy and outstanding safety in long-term follow-up data from the registrational clinical study, which underscores its potential to be a pioneering treatment option for patients with RRMM. We are very pleased with the approval of FUCASO® and hope it could benefit RRMM patients as the first approved BCMA CAR-T therapy in China." Ms. Jinhua Zhang, Chairman and Chief Executive Officer of IASO Bio, stated, "We are excited that FUCASO® was approved as a new drug, which is a significant milestone for our team. FUCASO® is not only IASO Bio's first commercialized product but is also the world's first commercially available fully-human CAR-T therapy. Furthermore, FUCASO® is the first self-developed and independently manufactured CAR-T cell therapy in China as well as China's first approved BCMA CAR-T product and first approved cell therapy for the treatment of MM in China. The NMPA's NDA approval of FUCASO® will help us in achieving our strategic goal of bringing groundbreaking treatment options, as well as new hope for a potential cure, to MM patients in need." About Multiple Myeloma (MM)Multiple Myeloma (MM) is a blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems, and bone fractures. For MM patients, common first-line drug treatments include proteasome inhibitors, immunomodulatory drugs, and alkylating agents. While treatment may result in remission, most patients will inevitably enter the relapsed or refractory stage as there's currently no cure. As a result, there is a significant unmet need for patients with relapsed or refractory multiple myeloma. According to Frost & Sullivan, new MM cases in China rose from 20,100 in 2018 to 22,400 in 2022 and are expected to increase to 25,700 by 2027. About FUCASO® (Equecabtagene Autoleucel)FUCASO® (Equecabtagene Autoleucel) is an innovative fully-human anti- BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully-human scFv, CD8a hinge and transmembrane, and 4-1BB-mediated co-stimulation and CD3ζ activation domains. Based on rigorous selection and screening of the molecular structures, and comprehensive in vivo and in vitro evaluation, FUCASO® has demonstrated rapid and potent efficacy as well as prolonged persistency in RRMM patients. FUCASO® (Equecabtagene Autoleucel) is approved by China's NMPA for the treatment of RRMM. Innovent and IASO Bio are responsible for joint development and commercialization of FUCASO® (Equecabtagene Autoleucel) for the treatment of RRMM in mainland China. Furthermore, Equecabtagene Autoleucel received Orphan Drug Designation (ODD) designation from the U.S. Food and Drug Administration (FDA) for the treatment of RRMM and obtained the U.S. FDA IND approval. Equecabtagene Autoleucel also received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations in February 2023 from the FDA. In addition to multiple myeloma, the NMPA has accepted another IND application for the new extended indication of Neuromyelitis Optica Spectrum Disorder (NMOSD). About Innovent Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune disease, metabolic disorder and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 35 valuable assets in the fields of cancer, metabolic disorder, autoimmune disease and other major therapeutic areas, with 9 approved products on the market. These include: TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection), Pemazyre® (pemigatinib oral inhibitor), olverembatinib(BCR ABL TKI), Cyramza® (ramucirumab), Retsevmo® (selpercatinib) and FUCASO® (Equecabtagene Autoleucel). An additional 2 assets are under NMPA NDA review, 6 assets are in Phase III or pivotal clinical trials, and 18 more molecules are in clinical studies. Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. Disclaimer: Innovent does not recommend any off-label usage. Note: TYVYT® (sintilimab injection) is not an approved product in the United States. BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States. TYVYT® (sintilimab injection, Innovent) BYVASDA® (bevacizumab biosimilar injection, Innovent) HALPRYZA® (rituximab biosimilar injection, Innovent) SULINNO® (adalimumab biosimilar injection, Innovent) Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan. CYRAMZA® (ramucirumab, Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Retsevmo® (selpercatinib, Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. About IASO BiotechnologyIASO Bio is a clinical stage biopharmaceutical company engaged in discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput chimeric antigen receptor T-cell (CAR-T) drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This pipeline includes a portfolio of over 10 novel products, including FUCASO® (Equecabtagene Autoleucel). Equecabtagene Autoleucel received New Drug Application (NDA) approval from China's National Medical Products Administration (NMPA) and U.S. FDA IND approval for the treatment of R/R MM. IASO also received Breakthrough Therapy Designation (BTD) from the NMPA in February 2021 and Orphan Drug Designation (ODD) from the FDA in February 2022, Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations from the FDA in February 2023. In addition to multiple myeloma, NMPA has approved IND application of FUCASO® for the new expanded indication of Neuromyelitis Optica Spectrum Disorder (NMOSD). Additionally, the company's in-house developed fully human CD19/CD22 dual-targeted CAR-T cell therapy received two IND clearances for treating relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory acute B-lymphoblastic leukemia (r/r B-ALL). It is currently in Phase I clinical trial for r/r B-NHL. It was also granted ODD for treatment of acute lymphoblastic leukemia by the FDA in October 2021. And the fully human monoclonal antibody targeting human CD19, IASO-782 Injection, received both FDA and NMPA IND approvals in June 2023 for use in U.S. and China clinical trials for Autoimmune hematological disorders, including primary immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). Leveraging its strong management team, innovative product pipeline, integrated manufactural and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfil unmet medical needs to patients in China as well as around the world. For more information, visitwww.iasobio.com or www.linkedin.com/company/iasobiotherapeutics. Innovent's Forward-Looking StatementsThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company") , are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
參與京都和服體驗、ZEN KOKYU和盆景工作坊等活動。品嘗完全日本產食材制作的美食，日本清酒ARAMASA和日本威士忌。TOHAKU CHAKAN於2023年7月14日開放。開放日期：2023年7月14日（星期五）至2024年1月28日（星期日）。 東京2023年6月30日 /美通社/ -- 獨立行政法人國立文化財機構運作的東京國立博物館（位於東京台東區，館長：Makoto Fujiwara；以下簡稱「東京國立博物館」）將在博物館內的一所日式住宅Okyokan開設TOHAKU CHAKAN（茶館）（開放日期：2023年7月14日至2024年1月28日）。 東京國立博物館位於東京上野，歷經150年傳承下來的收藏品現在約有12萬件。其中國寶89件，重要文化財649件（截至2023年4月），無論質和量都代表日本收藏的最高水准。 Okyokan是一座珍貴的日式房屋，通常不對公眾開放。它建於1742年，是位於名古屋市郊的Meigenin Temple的書院。後來，被搬至位於東京品川的Takashi Masuda (Donno)先生（三井物產第一任總裁、著名茶道家）的住所。1933年，Okyokan被捐贈給東京國立博物館。為了讓游客欣賞到日本江戶時代著名畫家Maruyama Okyo的（復制品）襖繪，同時體驗日本文化，這裡為游客准備了各種食物、飲料和活動。我們誠邀您抓住這個寶貴的有限時機，參觀Okyokan。 官網 → https://chakan-tokyo.com/ （計劃於7月10日開放）如有疑問，請聯系→ t.chakan@chakan-tokyo.com 面向來日本的外國游客：在東京國立博物館體驗真正的日本文化和活動 推薦活動涵蓋三個E： 環境(Environment)體驗(Experience)教育(Education) (1)禪呼吸法「ZEN KOKYU」禪呼吸法是基於18世紀著名禪宗Rinzai派創始人Hakuin Zenji在其著作《Yofune Kanwa》中傳承下來的呼吸技巧。由Yuki Shiina以「ZEN KOKYU」的形式重新復興，它經歷了歲月的考驗，如今仍在使用。 (2) 5分鍾和服體驗在Okyokan，客人可以體驗在京都精心定制的一件件和服。 (3) 盆景工作坊客人可以在TOHAKU CHAKAN欣賞到盆栽藝術家Kunio Kobayashi創作的盆景作品。 *本活動並非每天都有，具體日期和詳情將在官方網站公布。 食物 ARAMASA，木桶釀造的日本清酒ARAMASA是秋田縣的一家清酒釀造廠，回歸了江戶時代的傳統方法，將所有清酒都在木桶中釀造。 ICHIRO'S MALT，日本威士忌Ichiro's Malt是日本威士忌的代表。 供應日本各地精心挑選的食材制作的餐點提供各種輕食，如烏冬面、蕎麥面和稻荷壽司。周末還提供限量套餐，僅限預約使用。也可外帶。*餐點將於8月開始供應。 「K&K Canned Food」，選用最上等的食材制作「K&K Canned Food」系列罐裝食品在食材成分上沒有任何妥協。 「Daichi No Ume」百分之百有機成分制作完全有機的梅酒，由日本梅農精心培育的有機梅制成，被The CHOYA浸泡在有機糖和有機清酒酒中。 請從以下鏈接下載各個內容的圖像數據https://vectorincgroup.box.com/s/th7oulmliltn39xa4ndjvoi6oohvqeiy 活動信息TOHAKU CHAKAN，正宗的日本茶館位於東京國立博物館Okyokan-在東京體驗真正的日本文化- [開放日期] 2023年7月14日（周五）——2024年1月28日（周日）[休息日] 12月23日至1月1日期間的每周一（若周一是國定假日則為周二）以及其他假日 [開放時間] 10:00 - 16:30 (最後點單時間為16:00)[場地] 東京國立博物館的Okyokan [地址] 東京都台東區上野公園13-9 [交通方式]搭乘JR在上野站公園出口或鶯谷站南出口出站,步行10分鍾;乘坐地鐵在上野站或根津站下車,步行15分鍾搭乘京成電鐵在京成上野車站下車，步行15分鍾 官方網站：chakan-tokyo.com (計劃於7月10日開放)如有任何疑問，請聯系t.chakan@chakan-tokyo.com 提供英語客戶服務 提供免費Wi-Fi 票務信息進入TOHAKU CHAKAN需提前預約。入場、活動和餐飲票可供購買。根據使用情況，可能會有當日參與的機會。 [購買方式] 門票將於7月第二周開始銷售。詳情將在以下社交媒體賬號上公布。[Instagram] https://instagram.com/tohaku_chakan?igshid=MmIzYWVlNDQ5Yg==[Facebook] https://www.facebook.com/profile.php?id=100093664517434 公關支持Air Media Inc. 成立於2011年（總裁兼首席執行官：Ayako Kon；策劃師兼制作人：Nobuko Yonezawa） 根據客戶要求進行策劃工作。 從市場營銷到品牌推廣，從視頻制作（廣告、電視劇、電影、發布）到活動策劃，以及與國外公司的協調，Air Media提供與娛樂相關的廣泛內容。
Study sheds light on perceptions, behaviours and changes towards digitalisation in the aftermath of the COVID-19 pandemic SINGAPORE, July 3, 2023 /PRNewswire/ -- Reeracoen, a leading provider of human resource services in Singapore, has released its latest report titled "Employee Attitudes Towards Digitalisation in a Post-pandemic World", providing valuable insights into the impact of COVID-19 on Singapore workers and their readiness for digital transformation. In collaboration with Rakuten Insight Global, the study analysed 308 responses from three age groups to better understand Singapore workers' evolving attitudes and behaviours towards digitalisation. The report looks to bridge the gap in understanding and/or expectations between workers and employers, educating both parties with the aim of creating a better environment to nurture local talents for the future. Specifically, the survey assessed the effects of the COVID-19 pandemic on Singapore workers and their ability to adapt to the rapid digital transformation that's underway in Singapore and other countries worldwide. As businesses were compelled to accelerate their digitalisation efforts in the past few years, Reeracoen sought to determine whether Singapore's workers felt adequately equipped to embrace significant changes to the way they live and work. The report captured responses from both full-time and part-time workers, offering a comprehensive perspective across different work arrangements. Additionally, it explores workers' perceptions of their companies' readiness for digitalisation, any perceived upskilling gaps and opportunities, as well as the levels of digital preparedness among different employment types. Digitalisation attitudes varies from generation to generation Reeracoen commissioned the survey to understand employee attitudes towards digitalisation in a post-pandemic world across three demographics: Gen Z (23%), Gen Y (38%) and Gen X (39%). The results showed that Singapore full-time workers feel that the responsibility of Digitalization falls under: IT (34%) Govt (26%) Everyone (19%) HR (15%) Mine (6%) The survey results also revealed several insights between respondent groups: Less than half of the respondents have heard of Digitalization. Most respondents feel that their company is ready for Digitalization. Most full-time workers feel equipped to embrace "Digitalization", whereas most part-time workers feel ill-equipped to take on digital transformation. Most full-time workers feel supported by their company in terms of upskilling, whereas most part-time workers do not. Both full-time and part-time workers would most like their companies to roll out "Time off to upgrade/upskill", followed by "External training" and "Sponsored scholarships". The most popular upskilling platform both full-time and part-time workers are familiar with is SkillsFuture. "As the world continues to digitalise, there will be an ever-increasing demand for different ways of working - and this is a trend that will likely continue in 2023 and beyond," says Mr. Kenji Naito, Reeracoen's Group CEO. "To deal with this demand, Singapore based companies must evolve by first understanding their local talent pool, otherwise, they will have to compete globally for talents, which would be expensive and unsustainable. We believe that by providing insights into the changing trends as well as the evolving preferences of workers, we empower employers to attract and retain top talent effectively." In a landscape transformed by the pandemic and digitalisation, the report gives an insight into workers' perceptions, support systems, and perceived upskilling opportunities, which are all valuable intelligence for the planning and resourcing of any organisation. Combined with their continued dedication to serve as a bridge between the companies and candidates that they represent, Reeracoen has continued to fortify its position as a trusted partner for both companies and job-seekers Singapore wide. "Flexible working arrangements may be a good acquisition and retention strategy for companies in this global war for talent,” says Mr. Kenji Naito, Reeracoen Group CEO About Reeracoen Singapore Pte Ltd Reeracoen Singapore Pte Ltd is one of Singapore's leading recruitment agencies. Our extensive network allows us to source and match high-calibre talent to opportunities. Our clients enjoy peace of mind knowing that as part of the Neo-career group, Reeracoen is committed to delivering the same Japanese professionalism and service quality across our 10 offices in 6 Asian countries. For more information, visit https://www.reeracoen.sg/. About Rakuten Insight Global, Inc. Rakuten Insight Global, Inc. ("Rakuten Insight") is a wholly-owned online market research subsidiary of Rakuten Group, Inc., a global leader in internet services headquartered in Tokyo. Rakuten Insight, established in 1997, has offices in 61 countries and regions, providing market research to over 500 leading companies worldwide. For more information, visit https://insight.rakuten.com/.
A12 藝術空間
Type-C
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
